ArticleCNS neuroscience & therapeutics2026
Ocular Adverse Events Associated With Antidepressants: A Large-Scale Data Analysis From the FAERS Database.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveGlobal antidepressant use has risen substantially, raising concerns about their potential ocular adverse effects. Nevertheless, large-scale comprehensive assessments of ocular side effects associated with various classes of antidepressants remain limited.
methodsA retrospective pharmacovigilance analysis was performed using the FDA Adverse Event Reporting System (FAERS) from Q1 2015 to Q4 2024. Reports associated with antidepressants were systematically extracted, and disproportionality analyses were performed to identify potential associations with ocular adverse events (AEs).
results62,020 ocular AE reports were identified for 13,348 patients (median age, 44 years), with higher susceptibility observed in females. Norepinephrine-dopamine disinhibitors (NDDIs) showed the strongest association with eye disorders (IC 3.84, 95% CI 3.75-3.90), while selective serotonin reuptake inhibitors (SSRIs) showed the greatest number of positive associations across key ocular AEs. Analysis of the 36 antidepressants with sufficient case reports for ocular neuromuscular disorders revealed that 33 were associated with such disorders, most notably mydriasis, miosis, and anisocoria.
conclusionThis study delineates the ocular risks of antidepressants, highlighting higher toxicity for NDDIs and SSRIs and widespread associations with ocular neuromuscular disorders. Vigilant monitoring and early intervention are warranted to ensure safe clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.